ClinicalTrials.gg
RecruitingNCT07136714SEMAMOODUpdated Feb 6, 2026

Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

A Phase 4 interventional study of Semaglutide Injectable Product and Placebo in Major Depressive Disorder, sponsored by Nordsjaellands Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Nordsjaellands Hospital · Phase 4, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Depressive Disorder, Major with a site in Denmark — 10 open to participants now, 11 under way, none of them phase 3. Depressive Disorder, Major · Denmark.

Planned enrollment
10th of 36
116 · median 80
Started
2025
with 4 others
Phase 4
4 of 44
1 open now
Primary completion
2027-09
later than 7 of 10 live
Registered
40th of 44
by date

Among the 44 studies in Depressive Disorder, Major with a site in Denmark, this one is the 10th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 7 of the 10 other live ones, and was the 40th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 44 studies in Depressive Disorder, Major with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Depressive Disorder, Major with a site in Denmark, or all of them as a file.
02

Study summary

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing overweight or obesity. The treatment will be an add-on treatment to the patient's usual medication. The investigators hypothesize that adjunctive treatment with semaglutide, will lead to a significant improvement in mood compared to placebo in patients with MDD and overweight or obesity.

The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from start to follow-up after 26 weeks. The MDI measures the extent to which symptoms of depression have been present in the past two weeks.

Read the detailed description

This 26 week, randomized, double-blinded, placebo-controlled clinical trial investigate effects of semaglutide once-weekly vs. placebo on depressive symptoms in patients with unipolar disorder and comorbid obesity or overweight aged 18 years to 65 years. The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from week 0 to week 26.

Participants will be randomized to receive once-weekly injection of either semaglutide or placebo.

Patients will be treated for 26 weeks with an initial dose of semaglutide of 0.25 mg once weekly for four weeks, 0.50 mg once weekly for four weeks 1.0 mg for four weeks, 1.7 mg for four weeks and finally 2.4 mg for the remaining treatment period. Assessments will be conducted at weeks 0, 4, 8, 12, 16, 20, 24, and 26. Adherence and adverse events will be assessed during the entire treatment period. In addition, heart rate, blood pressure, height, body weight, waist and hip circumference will be recorded. The diagnosis of depression will be confirmed at baseline and depressive symptoms will be assessed with Hamilton Depression Rating Scale (HAM-D17) at baseline week 0, 12 and 26. MDI will be completed monthly. Participants will also complete questionnaires on physical activity, cognitive complaints, perceived stress, the reward system, Quality of life, alcohol use, and sleep quality at baseline and week 26.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • GLP-1
  • Glucagon-like peptide 1
  • Semaglutide
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Informed oral and written consent.
  2. Diagnosed with unipolar disorder according to the criteria of ICD10 (International Classification of Diseases, World Health Organization (WHO)) or the (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association
  3. Hamilton Depression Rating Scale, 17-items (HDRS-17)47 score ≥14,
  4. Age 18 years to 65 years (both included)
  5. (BMI) ≥27 kg/m2
  6. Able to speak and understand Danish

Exclusion criteria

Exclusion Criteria:

  1. Any significant medical disorder or conditions that contraindicate the drug, e.g., pregnancy, presence of known allergy GLP-1 receptor agonists, severe neurological disorder, on-going drug, or alcohol abuse
  2. Coercive measures
  3. Females of who are pregnant, breast-feeding or have the intention of becoming pregnant within the next 9 months (26 weeks plus two months after discontinuation of semaglutide), or are not using (during the whole study period) considered as highly effective (combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) intrauterine device - IUD, IUS, bilateral tubal occlusion, vasectomised partner, sexual abstinence)
  4. Patients treated with or other hormone therapy (except oestrogens).
  5. Any active substance abuse or dependence (except for nicotine)
  6. Impaired hepatic function (plasma liver transaminases >2 times upper normal limit).
  7. Impaired renal function (serum creatinine >150 μmol/l)
  8. Cardiac problems defined as decompensated heart failure ( class III/IV), unstable angina pectoris, and/or myocardial infarction within the last 12 months
  9. Hypertension with systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg
  10. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase >2 times upper normal limit). Receiving any experimental or pre-marketing drug within the last 3 months
  11. Use of diabetes medication or weight-lowering pharmacotherapy e.g. semagultid within the preceding 3 months
  12. Known type 1 and 2 diabetes or >48mmol/l
  13. Suicidal behaviour as judged by the investigator and based on clinical evaluation. At all contact with patient attendance (please see Table 1) possible suicidality will be evaluatedaccording to the guidelines. If the patient is evaluated as suicidal, the person will be excluded from the study and evaluated by a senior consultant in psychiatry, who will take further action.
  14. Any condition that the investigator feels would interfere with trial participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Wegovy once--weekly s.c titrated to max dose of 2.4 mg

    Drug: Semaglutide Injectable Product

  • Placebo comparator
    Placebo

    Saline s.c. once-weekly

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide (Wegovy) once-weekly injection s.c

  • DrugPlacebo

    Placebo (BD Posiflush) once-weekly injection s.c

06

What researchers measure

Primary outcomes

  1. Change in depressive symptoms

    Change in depressive symptoms measured by the Major Depression Inventory (MDI; 12-item self-report mood questionnaire). The scale ranges from 0 to 50, with higher scores indicating worse outcome.

    Time frame: From baseline to 26 weeks of treatment

Secondary outcomes

  1. Glycaemic control parameters (blood sampling)

    Changes in HbA1c levels

    Time frame: From baseline to 26 weeks of treatment

  2. Body weight

    Change in body weight in kilograms (kg).

    Time frame: From baseline to 26 weeks

  3. Waist circumference

    Change in waist circumference in centimeters (cm).

    Time frame: From baseline to 26 weeks of treatment

  4. Hamilton Depression Rating Scale, 17-items (HDRS-17) score

    Change in depressive symptoms measured by the Hamilton Depression Rating Scale, 17-items (HDRS-17) score. The scale ranges from 0 to 52, with higher scores indicating worse outcome.

    Time frame: From baseline to 26 weeks of treatment

  5. Functioning assessment short test (FAST) score

    Changes in Functioning assessment short test (FAST) score. Total score in the range 0-72, where higher scores reflect more serious functional impairment

    Time frame: From baseline to 26 weeks of treatment

07

Study locations

1 of 1 sites recruiting
  • Mental Health Centre North Zealand
    Hillerød, Denmark 3400, Denmark
    Recruiting
    • Maj Vinberg, MD, DMSc, Professor · ContactMaj.Vinberg@regionh.dk · +45 38643227
    • Christoffer Stanislaus, MD, ph.d.-student · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Individual Participant Data (IPD) will be shared upon reasonable and relevant requests, such as for meta-analyses. All IPD will be anonymized or de-identified to protect participants' privacy and in accordance with applicable regulations, including the GDPR.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 22, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136714
Lead sponsor
Nordsjaellands Hospital
Responsible party
Maj Vinberg (MD, DMSc, Professor, Nordsjaellands Hospital) — Principal investigator
First posted
Aug 22, 2025
Start date
Sep 11, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Maj Vinberg, MD, DMSc
Contact
maj.vinberg@regionh.dk
+ 45 38 64 32 27
Christoffer Stanislaus, MD, ph.d.-student
Contact
Christoffer.stanislaus@regionh.dk
Maj Vinberg, MD, PhD, DMSc
principal investigator · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion